Brief: Mereo Biopharma Says FDA Granted Orphan Drug Designation To Alvelestat For Treatment Of Alpha-1 Antitrypsin Deficiency
26/10/2021 15:12
Oct 26 (Reuters) - Mereo Biopharma Group PLC MAH0y.F :
* MEREO BIOPHARMA - U.S. FDA GRANTED ORPHAN DRUG DESIGNATION
TO
ALVELESTAT FOR TREATMENT OF ALPHA-1 ANTITRYPSIN DEFICIENCY
Source text for Eikon: ID:
Further company coverage: MAH0y.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mereo BioPharma
See all newsBrief: Sentynl Therapeutics And Mereo Biopharma Announce Option And License Agreement For Alvelestat In Alpha-1 Antitrypsin Deficiency-Associated Lung Disease
UK's Mereo BioPharma Q2 loss narrows on lower R&D spending
Brief: Mereo BioPharma Q2 Operating Income USD -7.03 Million
Brief: Mereo BioPharma Q1 Net Income USD -6.719 Million
Brief: Mereo BioPharma FY Revenue USD 500 Thousand Vs. IBES Estimate USD 520 Thousand